118 related articles for article (PubMed ID: 30754058)
1. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
Mauss S; Buendgens L; Christensen S; Ingiliz P; Berger F; Hüppe D; Simon KG; Lutz T; Schewe K; Boesecke C; Tacke F
Z Gastroenterol; 2019 Feb; 57(2):139-147. PubMed ID: 30754058
[TBL] [Abstract][Full Text] [Related]
2. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.
Tacke F; Boeker KHW; Klinker H; Heyne R; Buggisch P; Pathil A; Wiegand J; Cornberg M; Lange C; Berg T; Zeuzem S; Mauss S
Liver Int; 2020 Mar; 40(3):539-548. PubMed ID: 31241820
[TBL] [Abstract][Full Text] [Related]
3. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response.
Hsieh YC; Lee KC; Su CW; Lan KH; Huo TI; Wang YJ; Huang HC; Lin HC; Chu CJ; Huang YH; Hou MC
J Chin Med Assoc; 2021 May; 84(5):472-477. PubMed ID: 33742989
[TBL] [Abstract][Full Text] [Related]
4. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
Tacke F; Klinker H; Boeker KHW; Merle U; Link R; Buggisch P; Hüppe D; Cornberg M; Sarrazin C; Wedemeyer H; Berg T; Mauss S;
Hepatol Commun; 2022 Sep; 6(9):2488-2495. PubMed ID: 35666055
[TBL] [Abstract][Full Text] [Related]
5. Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
Watanabe T; Tokumoto Y; Joko K; Michitaka K; Horiike N; Tanaka Y; Tada F; Kisaka Y; Nakanishi S; Nonaka T; Yamauchi K; Hirooka M; Abe M; Hiasa Y
J Med Virol; 2017 Sep; 89(9):1567-1573. PubMed ID: 28165154
[TBL] [Abstract][Full Text] [Related]
6. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
7. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL;
Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072
[TBL] [Abstract][Full Text] [Related]
9. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
10. Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.
Dogan UB; Akin MS; Yalaki S
World J Gastroenterol; 2013 Dec; 19(46):8678-86. PubMed ID: 24379586
[TBL] [Abstract][Full Text] [Related]
11. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
Hiramatsu N; Inoue Y; Oze T; Kurashige N; Yakushijin T; Mochizuki K; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Hayashi N
J Gastroenterol; 2011 Nov; 46(11):1335-43. PubMed ID: 21858637
[TBL] [Abstract][Full Text] [Related]
13. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
Chadha N; Turner A; Sterling RK
J Viral Hepat; 2023 Jan; 30(1):73-78. PubMed ID: 36301045
[TBL] [Abstract][Full Text] [Related]
15. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
16. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
17. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
Olveira A; Domínguez L; Troya J; Arias A; Pulido F; Ryan P; Benítez LM; González-García J; Montes ML;
J Viral Hepat; 2018 Jul; 25(7):818-824. PubMed ID: 29476581
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
[TBL] [Abstract][Full Text] [Related]
19. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
20. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection.
Jin YJ; Shim JH; Kim GA; Yu E; Kim KM; Lim YS; Lee HC
BMJ Open; 2014 Nov; 4(11):e006255. PubMed ID: 25431223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
